E Finally A Real Cancer Diagnosis Breakthrough?

Todos Medical is a solid diagnostics company that utilizes blood tests for the early detection of cancer and neurodegenerative diseases. But is it a good investment? I took a deeper look and reached out to the company's CEO, Herman Weiss, to get the facts.

Todos Medical (TOMDF) has already made significant progress in multiple areas of interest. These include breast cancer screening and colorectal cancer screening. In addition, it was able to sign an agreement last year with Amarantus Biosciences (AMBS) to develop the LymPro Test 2.0. Matter of fact, this test recently reported impressive findings from one study known as LymPro PET 1. This is a promising speculative in-vitro diagnostics company, because it is gearing up to launch a breast cancer blood test in the coming months.

For starters, this company has a very innovative technology in place for blood tests. That’s because it has been able to develop something known as TBIA platform. TBIA stands for “Total Biochemical Infrared Analysis”. I believe that this biotech is onto something very special with this technology. That’s because other diagnostic companies for cancer screening use their technology to detect circulating malignant DNA. What that means is that their screening looks for cancer or biomarkers of tumors themselves. The problem with a blood test like that is that tumors aren’t detected until the cancer is already in the advanced stages. Well, Todos is taking another approach. Instead, it is looking to detect how the immune system reacts to tumors inside the body through a simple blood test. This is accomplished by looking at biochemical changes in plasma and peripheral blood mononuclear cells ((PBMCS)). The advantage of this type of method, is that a person’s cancer can be detected at a much earlier time frame. That’s not the only advantage in place. Other advantages of the TBIA platform are: Lower costs to produce, highly patient compliant, and easier to scale in terms of manufacturing.

1 2 3 4
View single page >> |

Disclosure: This article is part of a new “UnderCovered” series of exclusive articles featuring companies with limited coverage. Authors are compensated by TalkMarkets for their time, and ...

more
How did you like this article? Let us know so we can better customize your reading experience. Users' ratings are only visible to themselves.

Comments

Leave a comment to automatically be entered into our contest to win a free Echo Show.
Leslie Miriam 1 month ago Member's comment

This sounds very encouraging. I'll be keeping an eye on $TOMDF.

Hemant Latawa 1 month ago Member's comment

Immunology and diagnostic is an interesting phase in the diagnosis of cancer! The future and answers to diagnosis and treatment of cancer lies in the various aspects of immunology. RBNbHealthcare.com is also offering immunology therapeutics as a treatment option for advanced cancers! Hope to see good results for the research! https://rbnbhealthcare.com

Paul McGee 1 month ago Member's comment

Very impressive results.

Chuck Weston 1 month ago Member's comment

Terry/Herman, how did you evaluate the Lympro2.0 PET 1 data? I haven't seen that publicly released. And where did you see it could be as high as 90%? That would be great if it was, is that sens/spec or what? What are have KOLs or potential industry partners set as diagnostic goalposts?

Herman Weiss 1 month ago Member's comment

Chuck, i want to add, the quote of 'could be as high is 90%' was clearly aspirational based on targets that have been developed with pharma in mind, to your second question.

Herman Weiss 1 month ago Member's comment

Hi Chuck, Just logged in for the first time since this went live, and seeing some great feedback. We are putting together our data package, but need to take care of a few things before we can publicise it. The KOLs we have canvased and the Pharma companies have all told us that any diagnostic that pushes the diagnosis earlier will be highly sought after

David M. Green 1 month ago Member's comment

This question seems suspiciously unanswered.

Herman Weiss 1 month ago Member's comment

Sorry David, i have been traveling, please see my answer

David M. Green 1 month ago Member's comment

Thanks Herman Weiss. I'm impressed without how responsive you are to users' questions.

Chuck Weston 1 month ago Member's comment
Harry Goldstein 1 month ago Member's comment

I'd like to know this as well.

Herman Weiss 1 month ago Member's comment

Harry, Our KOLs and Pharma contacts are all eager as well

Chuck Weston 1 month ago Member's comment

A real shame Herman Weiss or Terry Chrisomalis won't answer this. You've had almost a week fellas. Seems to say it all....

Herman Weiss 1 month ago Member's comment

Sorry for the delay Chuck, no trying to be evasive, I was traveling for the last 2 weeks, There was a conference in Vegas and followed by investor meetings in NYC. To directly answer your question we are working on getting the data out publicly in the right time and forum. There is a process here we are trying to be cognisant of and stay within the lines.

Chuck Weston 1 month ago Member's comment

Dr. Herman Weiss, I appreciate your reply and hope the roadshow went well. Please forgive a squeaky wheel looking for grease. A few follow-ups:

1. Did Todos/Amarantus/Breakthrough apply for the ADDF/Gates Diagnostic Accelerator? 1b. Did that application include any PET comparison data? 1c. If not, why?

2. Are you saying KOLs and potential clinical partners have not given you any firm metrics to meet? 2b. From your second response am I to take it the firm would be pleased with approx 90%s/s? Given the prior history of this diagnostic, the market would appreciate clarity and disciplined talk when it comes to efficacy.

3. Did you have the Lympro PET1 data in hand before you finalized the acquisition/partnership?

Herman Weiss 1 month ago Member's comment

herman.w todosmedical.com

Herman Weiss 1 month ago Member's comment

Chuck, all excellent questions, but I would need to sign an NDA before diving deeper into the answers, happy to do so. Please reach out herman.w todosmedical.com

Dan Jackson 1 month ago Member's comment

Great news for both investors and cancer patients.

Terry Chrisomalis 1 month ago Author's comment

Yes it will be good in the future to detect cancer at an earlier stage.

Susan Miller 1 month ago Member's comment

As a socially responsible investor, this company is very appealing. $TOMDF

Terry Chrisomalis 1 month ago Author's comment

It is quite interesting, if they can pull it off in good fashion commercially they have a shot to do great things.

Branka Virily 1 month ago Member's comment

Big news.

Terry Chrisomalis 1 month ago Author's comment

yes good for both investors and for shareholders of the company. Will start to improve as more territories are commercialized.

Barry Glassman 1 month ago Member's comment

Nice!

Duanne Johnson 1 month ago Member's comment

For those of us who aren't big in this sector - can someone sum this up for us lay investors? I don't need to understand the science - this place doesn't publish fake news. But what does it all mean in simple terms?

Terry Chrisomalis 1 month ago Author's comment

basically it's a cheaper blood test and it can detect cancer at an earlier stage than other tests. That's because it doesn't look at detecting cancer itself, it detects how your immune system reacts to the cancer.

Brian Casey 1 month ago Member's comment

Can this test work with "cold" immune systems? By "cold" I mean an immune system that doesn't appear to pick up on malignant cells that would normally be terminated. It occurs a lot in melanoma patients.

Herman Weiss 1 month ago Member's comment

Hi Brian, There is a point in time when the immune system does indeed react to the malignant change and shift from tumor suppressive to tumor tolerant and there is an interaction that the tumor 'turns off' the host reaction to fight it, we have shown data indicating we can still pick up these changes.

Duanne Johnson 1 month ago Member's comment

Thanks. Do you know if any competitors are developing anything similar?

Herman Weiss 1 month ago Member's comment

There are competitors looking at circulating DNA from tumor cells, but this usually happens later in the disease process and not early

Bill Myers 1 month ago Member's comment

I find this kind of stuff really fascinating.

Terry Chrisomalis 1 month ago Author's comment

Yes the science of it is quite interesting.